Inclusion Criteria:

- Must have a histologically confirmed B-cell malignancy (defined as FL [any grade],
DLBCL, MCL or SLL/CLL);

- Male or non-pregnant, non-lactating females age ≥18 years;

- Ability to swallow and retain oral medication.;

- Have failed at least one prior therapy and have documentation of either, relapsed
disease, or refractory disease (i.e., no response or stable disease on their last
regimen of therapy);

- ECOG performance status 0 or 1;

- All clinically significant toxicities from prior therapy must have fully resolved;

- Must have discontinued treatment with monoclonal antibodies for a minimum of 90 days
prior to first dose of AT-101, or have objective documentation of disease progression
if within 90 days of monoclonal antibody administration;

- Patients with FL, DLBCL, MCL, and SLL with normal lymphocyte counts must have at
least one bi-dimensional lesion that is radiographically measurable (skin lesions,
palpable lymph nodes, and bone marrow as the only site of disease are not considered
measurable disease);

- Patients with SLL whose lymphocytes are elevated at baseline or CLL must have
palpable lymph nodes and/or disease localized to the bone marrow per the
NCI-Sponsored Working Group Guidelines for CLL.

Exclusion Criteria:

- Requirement of systemic corticosteroids within 7 days prior to and during AT-101
administration;

- Must not have received anti-cancer therapy within 28 days of first dose of AT-101.
Cannot have received hormonal agents or biologic dose modifiers (with the exception
of HRT) or any investigational treatments within 28 days of treatment with AT-101;

- Patients with CNS lymphoma, HIV-related lymphoma, symptoms suggesting HIV infection
or active auto-immune hemolytic anemia are excluded;

- Previous treatment with gossypol, or are hypersensitive to its excipient are
excluded;

- Patients who have an uncontrolled, concurrent illness are also excluded.